Eugia Receieves FDA approval for Zoledronic Acid 5 mg/100 mL Single-Dose Vials!
Published: December 11, 2017
On December 08, 2017 Eugia received FDA approval for Zoledronic Acid which is a bisphosphonate indicated for treatment of Paget’s disease of bone in men and women.
Zoledronic Acid has an estimated annual market of $17.5 million according to IMS data running through October 2017.